Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
- TOMBULOĞLU, MURAT
- Vura, Filiz
- Ozdemirkiran, Fusun
- Payzin, Bahriye
- Kiper, H. Demet
- Kabukcu, Sibel
- Cagliyan, Gulsum Akgun
- Kahraman, Selda
- Sevindik, Omur Gokmen
- Ceylan, Cengiz
- Kadikoylu, Gurhan
- ŞAHİN, FAHRİ
- Keskin, Ali
- Arslan, Oyku
- Gorgun, Gulnur
- Bolaman, Zahit
- Buyukkececi, Filiz
- Bilgir, Oktay
- Alacactoglu, İNCİ
- ÖZCAN, MEHMET ALİ
- SAYDAM, GÜRAY
- Gokgoz, Zafer
DOIAbstract
Objective: Immune thrombocytopenia (ITP) is an immune-mediated disease characterized by transient or persistent decrease of the platelet count to less than 100x109/L. Although it is included in a benign disease group, bleeding complications may be mortal. With a better understanding of the pathophysiology of the disease, thrombopoietin receptor agonists, which came into use in recent years, seem to be an effective option in the treatment of resistant cases. This study aimed to retrospectively assess the efficacy, long-term safety, and tolerability of eltrombopag in Turkish patients with chronic ITP in the Aegean region of Turkey
Add to ORKG